Prof. Giovannoni discusses biomarkers used to detect remyelination and opicinumab, a LINGO-1 inhibitor, which was one of the first remyelination therapies to show initial promise. To find out more, visit www.abcam.com/MS
Connect with us
Visit us on: www.abcam.com
Facebook: / abcam
Twitter: / abcam
Instagram: / abcamlive
1 авг 2024